Connect with us


TDR’s Top 5 Psychedelic Developments For The Week Of April 25

Welcome to TDR’s review of the Top 5 Psychedelic developments for the week of April 25. Aside from presenting a synopsis of events, we provide market…



Welcome to TDR’s review of the Top 5 Psychedelic developments for the week of April 25. Aside from presenting a synopsis of events, we provide market commentary to summarize the week that was for publicly-listed companies.

5. COVID-19: Methamphetamine Use Rises Significantly Since Lockdown

Methamphetamine use has significantly increased and remained elevated since the August 2021 COVID-19 lockdown. Police wastewater figures show use more than doubled between July and September 2021, and has stayed well above the historical average right through to January 2022, the most recent available figures showed.

A social worker believes the drug is far more entrenched in society now than it was before COVID-19 and that it is not uncommon for children to be using it – some as young as eight and nine years old.

4. Maryland Senators Propose Free Psychedelics for Veterans with PTSD

A group of 10 Maryland Senators is co-sponsoring a new bill proposing to establish a state fund to provide military veterans suffering from post-traumatic stress disorder (PTSD) free access to a range of psychedelic therapies

Approval of the bill (SB 709) would create the Post-Traumatic Stress Disorder Alternative Therapies Fund, which would provide “cost-free” access to alternative therapies for veterans with PTSD. Per the bill, alternative therapies may include psychotherapy treatment with psychedelic substances such as MDMA, psilocybin, and ketamine, and hyperbaric oxygen therapy. 


Depression Decreases After Psilocybin Treatment, According To The Lancet


3. Psychedelic ETF Falls Double Digits Amid Broad Market Carnage

The biggest psychedelic stocks generally fell hard this past week, underperforming the peer biopharma indexes. The Horizon Psychedelic Stock Index ETF (PSYK) shed ↓11.28%, while the Nasdaq Junior Biotechnology Index (6.97%) and Nasdaq Biotechnology Ishares ETF (↓5.19%) held up relatively better. The broad market slumped for a fourth consecutive week, with NASDAQ 100 ↓3.47% and S&P 500 ↓3.05% and cratering to end the week. Here’s how the Health Care (Biotechnology) sector performed:

Weekly period technical snapshot, PSYK ETF:

Relative Strength Index (14)22.09Exponential Moving Average (10)3.46
Stochastic %K (14, 3, 3)14.96Simple Moving Average (10)3.4
Commodity Channel Index (20)−113.20Exponential Moving Average (20)4.04
Average Directional Index (14)50.67Simple Moving Average (20)3.85
Awesome Oscillator−1.69Exponential Moving Average (30)4.64
Momentum (10)−0.99Simple Moving Average (30)4.73
MACD Level (12, 26)−0.84Exponential Moving Average (50)5.82
Stochastic RSI Fast (3, 3, 14, 14)64Simple Moving Average (50)6.03
CompanyTickerPrice ($)Weekly Change (%)WoW Volume TrendMarket Cap (s/o)
ATAI Life SciencesATAI4.29-10.25US$689.4M
GH ResearchGHRS14.56-14.35US$757.4M
COMPASS PathwaysCMPS9.06-28.15US$380.7M
Mind MedicineMNMD0.80-8.04US$337.9M
Cybin Inc.CYBN0.576-20.22US$94.6M
Revive TherapeuticsRVVTF0.254-9.42US$81.0M
Numinus WellnessNUMI0.45-4.25C$91.7M
Field Trip HealthFTRP1.06-14.51US$61.6M
Small PharmaDMT0.20C$63.9M
Mindset PharmaMSET0.43-17.30C$39.0M
Awakn Life SciencesAWKN1.23-5.38C$34.4M
Mydecine InnovationsMYCO1.84-21.73C$6.9M

In the news…

Biomind Labs doses first subject in Phase I/IIa clinical trial of its DMT-based inhaled formulation BMND01 for treatment-resistant depression.

Field Trip Health has received unanimous board approval to complete a reorganization that will result in the separation of its Field Trip Discovery and Field Trip Health divisions into two independent public companies. Field Trip Discovery will be renamed Reunion Neuroscience Inc. and Field Trip Health will be renamed Field Trip Health and Wellness Ltd. 

Filament Health has been issued a fourth patent for the extraction and standardization of natural psilocybin and associated psychedelic compounds. 

Gh Research: Zacks Investment Research lowered shares of GH Research from a hold rating to a sell rating in a report released on Thursday morning, reports.

Nirvana Life Sciences announced an update on licensing and development for its Vancouver Lab facility.

Optimi Health will be inaugurating its recently completed psilocybin cultivation facility with a grand opening event and reception for members of the media, investors and other stakeholders relevant to the company’s developing position as a leading supplier in the field of psychedelic and functional mushrooms on Friday, May 27th, 2022.

Revive Therapeutics has provided an update on Phase 3 of its Bucillamine clinical trial, a drug being developed in Phase 3 clinical trials to treat coronavirus.  There is the potential for Bucillamine to be eligible for funding from the federal government through Biomedical Advanced Research and Development Authority, or BARDA for short.  

Tryp Therapeutics announced that the first patient has been dosed in the company’s Phase II clinical trial for its lead candidate, TRP-8802. In combination with psychotherapy, TRP-8802 is intended to serve as a potential treatment of Binge Eating Disorder.

University of Nevada Las Vegas researchers study psychedelic drugs for use in mental health.

Vancouver Island University is hoping to expand that toolbox by becoming the first accredited university in Canada to offer a graduate certificate program in using psychedelics such as psylocibin, or “magic mushrooms,” in mental health care. The program looks to kick of this September.

Wellbeing Digital Sciences subsidiary, IRP Health Ltd., has been approved as part of the Chronic Pain Centre of Excellence for Canadian veterans.

2. Colorado Senators Approve House-Passed MDMA Legalization Bill In Committee

A Colorado Senate committee on Wednesday unanimously approved a House-passed bill to align state statute to legalize MDMA prescriptions if and when the federal government ultimately permits such use. The House cleared the bill earlier this month, and now the Senate Health & Human Services Committee approved it in a 5-0 vote, sending it to the Committee of the Whole.

MDMA-assisted therapy has already shown incredible results in the stage three clinical trials for individuals suffering from severe PTSD. I ask for your support on this bill.

Colorado Senator, Joann Ginal (D)

The MDMA legislation, meanwhile, would legalize “prescribing, dispensing, transporting, possessing, and using” MDMA if the U.S. Food and Drug Administration (FDA) approves the substance as a prescription drug.

Furthermore, the bill states that that MDMA is “highly effective if paired with talk therapy and counseling” and notes that “it is widely expected that the federal Food and Drug Administration will approve MDMA-assisted therapy for prescription use for PTSD as soon as 2023.”

1. Colorado Bill To Legalize MDMA Prescriptions Heads To Governor Following Senate Passage

The Colorado Senate on Friday approved a House-passed bill to align state statute to legalize MDMA prescriptions if and when the federal government ultimately permits such use, sending the measure to the governor.

The House cleared the legislation earlier this month before transmitting it to the Senate, where it passed out of committee and on the floor without amendments by a vote of 34-0. That means it’s now moving to the desk of Gov. Jared Polis (D).

The post TDR’s Top 5 Psychedelic Developments For The Week Of April 25 appeared first on The Dales Report.

Read More

Continue Reading


Cruise Line Drops Pre-Cruise Covid Testing Rule

The major cruise lines walk a delicate line. They need to take the actual steps required to keep their passengers safe and they also need to be aware of…



The major cruise lines walk a delicate line. They need to take the actual steps required to keep their passengers safe and they also need to be aware of how things look to the outside public. It's a mix of practical covid policy balanced with covid theater.

You have to do the right thing -- and Royal Caribbean International (RCL) - Get Royal Caribbean Group Report, Carnival Cruise Lines (CCL) - Get Carnival Corporation Report, and Norwegian Cruise Lines (NCLH) - Get Norwegian Cruise Line Holdings Ltd. Report have been doing that with very meticulous protocols-- but you also have to show the general public you're taking the pandemic seriously. The cruise industry has been under the microscope of both public perception and the Centers for Disease Control (CDC) since covid first appeared.

That's not because you're likely to get infected on a cruise ship than at a concert, sporting event, theme park, restaurant, or any other crowded space. It's because when you get sick at one of those locations nobody can pinpoint the source of your infection

Cruises last from 3 days to 7 days or even longer and that means that some people will get covid onboard and that will be blamed on the cruise industry. To mitigate that Carnival, Royal Caribbean, and Norwegian have rigid protocols in place that require passengers 12 and over to be vaccinated as well as pre-cruise covid tests taken no more than two days before your cruise leaves.

Once cruise line has dropped that testing requirement (at least on a few sailings) and that could lead Royal Caribbean, Carnival, and Norwegian to follow. 

Sina Schuldt/picture alliance via Getty

Holland America Drops Some Covid Testing

As the largest cruise lines sailing from the U.S., Royal Caribbean, Carnival, and Norwegian don't want to be the first to make major covid policy changes. They acted more or less in tandem when it came to loosening, then dropping mask rules and have generally followed the lead of the CDC, even when that agency's rules became optional.

Now, Holland America cruise line has dropped pre-cruise covid testing on a handful of cruises. It's a minor move, but it does provide cover and precedent for Royal Caribbean, Carnival, and Norwegian to eventually do the same.

"Holland America Line becomes the first US-based cruise line to remove testing for select cruises. Unfortunately for those taking a cruise from the United States, the new protocols are only in place for certain cruises onboard the company’s latest ship, the Rotterdam, in Europe," Cruisehive reported.

The current CDC guidelines do recommend pre-cruise testing, but the cruise lines into following those rules. By picking cruises sailing out of Europe, Holland America avoids picking a fight with the federal agency just yet, but it will be able to gather data as to whether the pre-cruise testing actually helps.

Holland America has not changed its vaccination requirements for those cruises which mirror the 12-and-up rule used by Royal Caribbean, Carnival, and Norwegian.

Some guests have called for the end of the testing requirement because they believe it's more theater than precaution because people can test and then contract covid while traveling to their cruise.

The Current Cruise Protocols Work

Royal Caribbean President Michael Bayley does expect changes to come in his cruise line's covid protocols, and he talked about them during Royal Caribbean's recent President's Cruise, the Royal Caribbean Blog reported.

"I think pre cruise testing is going to be around for another couple of months," Bayley told passengers during a question and answer session. "We obviously want it to go back to normal, but we're incredibly cognizant of our responsibilities to keep our crew, the communities and our guests safe."

People do still get covid onboard despite the crew being 100% vaccinated and all passengers 12 and over being vaccinated, but the protocols have worked well when it comes to preventing serious illness.

Bayley said that the CDC shared some information with him in a call.

"The cruise industry sailing out of the US ports over the past 12 months and how many people have been hospitalized with Covid and how many deaths occurred from Covid from people who'd sailed on the industry's ships, which is in the millions," he said, "And the number of people who died from COVID who'd sailed on ships over the past year was two."

That success may be why the major cruise lines are reluctant to make changes. The current rules, even if they're partially for show, have been incredibly effective.

"Two is terrible. But but but against the context of everything we've seen, that's it's truly been a remarkable success." he added.

Read More

Continue Reading


Tesla Rivals Challenge Its Lead as Nio Sets Encouraging Record

Tesla’s rivals are not even coming close to producing and delivering EVs at the same rate as the Austin, Texas-based market leader.



Tesla's rivals are not even coming close to producing and delivering EVs at the same rate as the Austin, Texas-based market leader.

Electric vehicle makers have been struggling over the last two years to produce and deliver cars, trucks and SUVs despite obstacles such as supply chain disruptions, semiconductor shortages and factory shutdowns caused by the covid pandemic.

The industry's leading EV manufacturer Tesla  (TSLA) - Get Tesla Inc. Report on July 2 said that plant closures at its Shanghai gigafactory in April and May and supply chain disruptions led to a smaller number of deliveries than expected in its second quarter ending June 30 with 254,695, which was 26.7% higher than the same period in 2021, but 17.7% lower than its record of 310,048 delivered in the first quarter of 2021. Analysts were originally expecting about 295,000 deliveries.

Tesla's production declined to 258,580 vehicles in the second quarter compared to 305,407 in the first quarter. It had produced 305,840 vehicles in the fourth quarter of 2021.

Tesla's rivals are not even coming close to producing and delivering EVs at the same rate as the Austin, Texas-based market leader. But they keep trying.


Tesla Rivals Struggle to Produce and Deliver Volume of EVs

Tesla rival Nio  (NIO) - Get NIO Inc. American depositary shares each representing one Class A 蔚来汽车 Report on July 1 said that it had delivered 12,961 vehicles in June for a 60.3% year-over-year increase and its highest number of monthly deliveries ever. The company also reported 25,059 EVs delivered in the three months ending June 2022, increasing by 14.4% year-over-year. Nio has delivered a cumulative 217,897 EVs as of June 30.

NIO on June 15 rolled out its ES7, a new mid-large five-seat smart electric SUV, which is the first SUV product based on NIO's latest technology platform Technology 2.0. NIO also launched the 2022 ES8, ES6 and EC6 equipped with the upgraded digital cockpit domain controller and sensing suite, enhancing the computing and perception capabilities as well as digital experience of the vehicles. The company expects to start deliveries of the ES7 and the ES8, ES6 and EC6 in August.

Chinese EV maker XPeng  (XPEV) - Get XPeng Inc. American depositary shares each representing two Class A 小鹏汽车 Report on July 1 said it delivered 15,295 vehicles in June, a 133% increase year-over-year; 34,422 in the second quarter ending June 30 for a 98% increase year-over-year and 68,983 in the first six months of the year for a 124% increase year-over year.

The Guangzhou, China-based company said in August it will begin accepting orders for its new G9 SUV with an official launch in September.

Beijing-based Li Auto  (LI) - Get Li Auto Inc. Report on July 1 said it delivered 13,024 EVs in June, a 68.9% increase year-over-year and 28,687 in the second quarter ending June 30 for a 63.2% increase year-over-year. The company on June 21 began taking orders for its Li L9 SUV and recorded 30,000 orders as of June 24, according to a statement. Test drives will begin July 16 with deliveries beginning by the end of August.

GM Follows Behind Tesla and Other Rivals

General Motors  (GM) - Get General Motors Company Report had 7,300 EV sales in the second quarter, according to a July 1 statement. The Detroit automaker's sales included deliveries of the BrightDrop Zevo 600 delivery van, GMC Hummer EV pickup, and the resumption of the Chevrolet Bolt EV and Bolt EUV production.

GM said the Cadillac Lyriq production is accelerating, with initial deliveries in process. Orders for the 2023 model year sold out within hours and preorders for the 2024 model opened on June 22.

The company said it will gradually increase production of the Cadillac Lyriq and GMC Hummer EV Pickup in the second half of 2022. 

Read More

Continue Reading

Spread & Containment

Tesla EV deliveries fall nearly 18% in second quarter following China factory shutdown

Tesla delivered 254,695 electric vehicles globally in the second quarter, a nearly 18% drop from the previous period as supply chain constraints, China’s…



Tesla delivered 254,695 electric vehicles globally in the second quarter, a nearly 18% drop from the previous period as supply chain constraints, China’s extended COVID-19 lockdown and challenges around opening factories in Berlin and Austin took their toll on the company.

This is the first time in two years that Tesla deliveries, which were 310,048 in the first period this year, have fallen quarter over quarter. Tesla deliveries were up 26.5% from the second quarter last year.

The quarter-over-quarter reduction is in line with a broader supply chain problem in the industry. It also illustrates the importance of Tesla’s Shanghai factory to its business. Tesla shuttered its Shanghai factory multiple times in March due to rising COVID-19 cases that prompted a government shutdown.

Image Credits: Tesla/screenshot

The company said Saturday it produced 258,580 EVs, a 15% reduction from the previous quarter when it made 305,407 vehicles.

Like in other quarters over the past two years, most of the produced and delivered vehicles were Model 3 and Model Ys. Only 16,411 of the produced vehicles were the older Model S and Model X vehicles.

Tesla said in its released that June 2022 was the highest vehicle production month in Tesla’s history. Despite that milestone, the EV maker as well as other companies in the industry, have struggled to keep apace with demand as supply chain problems persist.

Read More

Continue Reading